Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Epigenetic Regulation01:46

Epigenetic Regulation

28.7K
Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
28.7K
Epigenetic Regulation01:37

Epigenetic Regulation

3.5K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
3.5K
Epigenetic Regulation01:46

Epigenetic Regulation

24.1K
24.1K
Chromatin Modification in iPS Cells01:32

Chromatin Modification in iPS Cells

1.5K
Chromatin modification alters gene expression; therefore, scientists can add histone-modifying enzymes, histone variants, and chromatin remodeling complexes to somatic cells to aid reprogramming into pluripotent stem (iPS) cells.
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...
1.5K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Redefining light-chain smoldering multiple myeloma: prevalence and progression risk.

Leukemia·2026
Same author

Exploring the Functional Impact of Individual <i>DDX41</i> Variants With a Fast and Robust Cell-Based Method.

Human mutation·2026
Same author

Mosaic Chromosomal Alterations Identify Ultra-High Risk Clonal Hematopoiesis in Patients With Lymphoma Undergoing Intensive Chemotherapy.

American journal of hematology·2026
Same author

Bone marrow immunosuppressive states associate with survival after guadecitabine and atezolizumab therapy in HMA-R/R MDS.

Blood neoplasia·2026
Same author

Identifying High-Risk Smoldering Multiple Myeloma for Early Intervention.

JAMA oncology·2026
Same author

Validity of The Danish National Chronic Myeloid Neoplasia Registry.

Clinical epidemiology·2026

Related Experiment Video

Updated: May 4, 2026

Repressing Gene Transcription by Redirecting Cellular Machinery with Chemical Epigenetic Modifiers
10:28

Repressing Gene Transcription by Redirecting Cellular Machinery with Chemical Epigenetic Modifiers

Published on: September 20, 2018

6.1K

Predicting response to epigenetic therapy.

Marianne B Treppendahl, Lasse S Kristensen, Kirsten Grønbæk

    The Journal of Clinical Investigation
    |January 3, 2014
    PubMed
    Summary

    Predicting cancer treatment response to epigenetic drugs is crucial. This review overviews biomarkers that may indicate efficacy for FDA- and EMA-approved epigenetic therapies, aiding personalized medicine.

    Area of Science:

    • Oncology
    • Epigenetics
    • Pharmacology

    Background:

    • Epigenetic drugs offer novel cancer treatment strategies.
    • Patient responses to epigenetic therapies vary significantly.
    • Predicting treatment efficacy is essential for optimizing patient outcomes.

    Purpose of the Study:

    • To review and summarize pretreatment biomarkers for predicting epigenetic drug efficacy.
    • To identify markers relevant to FDA- and EMA-approved epigenetic agents.

    Main Methods:

    • Literature review of preclinical and clinical studies.
    • Analysis of reported clinical parameters and molecular targets.
    • Focus on biomarkers associated with approved epigenetic drugs.

    Main Results:

    More Related Videos

    Epigenetic Engineering of K562 Cells: Dual-Vector Episomal Strategy for Stable Targeted DNA Methylation using dCas9-DNMT3A and -HDAC1 Fusion Proteins
    09:56

    Epigenetic Engineering of K562 Cells: Dual-Vector Episomal Strategy for Stable Targeted DNA Methylation using dCas9-DNMT3A and -HDAC1 Fusion Proteins

    Published on: October 31, 2025

    694
    In Vitro Selection of Engineered Transcriptional Repressors for Targeted Epigenetic Silencing
    10:44

    In Vitro Selection of Engineered Transcriptional Repressors for Targeted Epigenetic Silencing

    Published on: May 5, 2023

    2.6K

    Related Experiment Videos

    Last Updated: May 4, 2026

    Repressing Gene Transcription by Redirecting Cellular Machinery with Chemical Epigenetic Modifiers
    10:28

    Repressing Gene Transcription by Redirecting Cellular Machinery with Chemical Epigenetic Modifiers

    Published on: September 20, 2018

    6.1K
    Epigenetic Engineering of K562 Cells: Dual-Vector Episomal Strategy for Stable Targeted DNA Methylation using dCas9-DNMT3A and -HDAC1 Fusion Proteins
    09:56

    Epigenetic Engineering of K562 Cells: Dual-Vector Episomal Strategy for Stable Targeted DNA Methylation using dCas9-DNMT3A and -HDAC1 Fusion Proteins

    Published on: October 31, 2025

    694
    In Vitro Selection of Engineered Transcriptional Repressors for Targeted Epigenetic Silencing
    10:44

    In Vitro Selection of Engineered Transcriptional Repressors for Targeted Epigenetic Silencing

    Published on: May 5, 2023

    2.6K
    • Various clinical and molecular markers have been investigated.
    • Results from previous studies show variable predictive value.
    • Ongoing research aims to optimize predictive marker identification.

    Conclusions:

    • Identifying reliable pretreatment predictors is valuable for epigenetic cancer therapy.
    • This overview provides insights into potential biomarkers for personalized epigenetic treatment strategies.